Review
Biotechnology & Applied Microbiology
Bin Hao, Li Wei, Yusheng Cheng, Zhifang Ma, Jingyu Wang
Summary: Prostate cancer is the second most common cancer in men globally. Early diagnosis is crucial due to the lack of obvious symptoms in the early stage. Highly sensitive and precise diagnostic methods, as well as targeted therapy regimens, play key roles in the treatment of prostate cancer.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Oncology
Hao Liang, Yang Liu, Jiao Guo, Maoyang Dou, Xiaoyi Zhang, Liyong Hu, Jun Chen
Summary: Prostate cancer is a common malignant cancer of the male genitourinary system. Immunotherapy has shown initial success in the treatment of advanced prostate cancer.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Anna S. Koerner, Ryan H. Moy, Sandra W. Ryeom, Sam S. Yoon
Summary: Gastric cancer is a common and deadly disease worldwide. Many patients are diagnosed with unresectable advanced disease due to the ambiguous symptoms. However, some patients have locally advanced gastric cancer (LAGC), which can be treated with surgical resection and perioperative chemotherapy. The optimal treatment for LAGC varies for different subtypes, but promising treatments based on molecular subtypes and biomarkers of LAGC are on the horizon.
Article
Multidisciplinary Sciences
Joseph M. Chan, Samir Zaidi, Jillian R. Love, Jimmy L. Zhao, Manu Setty, Kristine M. Wadosky, Anuradha Gopalan, Zi-Ning Choo, Sitara Persad, Jungmin Choi, Justin LaClair, Kayla E. Lawrence, Ojasvi Chaudhary, Tianhao Xu, Ignas Masilionis, Irina Linkov, Shangqian Wang, Cindy Lee, Afsar Barlas, Michael J. Morris, Linas Mazutis, Ronan Chaligne, Yu Chen, David W. Goodrich, Wouter R. Karthaus, Dana Pe'er, Charles L. Sawyers
Summary: Drug resistance in cancer is often associated with tumor cell lineage plasticity. The molecular mechanisms driving this plasticity have not been fully understood. This study shows that prostate cancer plasticity is initiated in a population of cells with mixed luminal-basal phenotype and is dependent on increased JAK and FGFR activity. Single-cell analysis in patients with metastatic disease confirms the presence of mixed-lineage cells with increased JAK/STAT and FGFR signaling.
Article
Oncology
Akira Yokomizo, Hirofumi Koga, Kazuto Ito, Yutaka Takezawa, Motokiyo Komiyama, Kazuo Nishimura, Junji Yonese, Katsuyoshi Hashine, Naoya Masumori, Gaku Arai, Shiro Saito, Mitsuru Shinohara, Nobuaki Shimizu, Atsushi Yamauchi, Takefumi Satoh, Tatsuo Tochigi, Mikio Kobayashi, Hiroyuki Fujimoto, Ken-ichi Kakimoto, Iwao Fukui, Taiji Tsukamoto, Miwako Nozaki, Katsuyuki Karasawa, Masaru Hasumi, Mikinobu Ohtani, Hiromichi Ishiyama, Masaaki Kuwahara, Masaoki Harada, Yasuo Ohashi, Toshihiko Kotake, Tadao Kakizoe, Kazuhiro Suzuki, Seiji Naito, Hidetoshi Yamanaka
Summary: The study found that in patients with locally advanced prostate cancer, intermittent ADT was significantly favored in patient-reported outcomes compared to continuous ADT, particularly in terms of FACT-P total score, physical well-being score, and functional score.
Article
Oncology
Takashi Ogata, Rihito Aizawa, Kiyonao Nakamura, Takashi Kobayashi, Shusuke Akamatsu, Eijiro Nakamura, Osamu Ogawa, Takashi Mizowaki
Summary: This study aimed to evaluate the benefit of long-term adjuvant hormonal therapy in combination with high-dose intensity-modulated radiation therapy for locally advanced prostate cancer patients with multiple unfavorable risks. The results showed that disease controls were significantly better in the adjuvant hormonal therapy cohort compared to the early salvage hormonal therapy cohort. There was no significant difference in overall survival rates between the two groups.
ANTICANCER RESEARCH
(2023)
Review
Oncology
Mario Terlizzi, Elaine Johanna Limkin, Yasmina Moukasse, Pierre Blanchard
Summary: The management of patients with biochemical recurrence after prostatectomy has changed significantly in recent years. Close monitoring of prostate-specific antigen (PSA) and early salvage radiotherapy (RT) have become the standard of care. However, uncertainties remain regarding the management of high-risk patients and the role of imaging.
Review
Oncology
Matt Shirley
Summary: Relugolix (Orgovyx(R)) is an orally active nonpeptide GnRH receptor antagonist that provides rapid testosterone suppression and is indicated in the USA and EU for the treatment of advanced prostate cancer. In a phase III trial, relugolix demonstrated sustained castration rates >90% over 48 weeks, which were comparable to leuprolide, but with potentially improved cardiac safety. With its rapid and sustained testosterone suppression, oral administration, and potential cardiovascular benefits, relugolix presents a valuable treatment option for men with advanced prostate cancer.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Qiaoqiao Shu, Xianjun Li, Xi Chen, Yue Chen, Liang Cai
Summary: An 84-year-old man with prostate cancer underwent PET/CT for staging, which showed no significant abnormal tracer accumulation in Ga-68-prostate-specific membrane antigen PET/CT but elevated tracer uptake in F-18-OC (F-18-AlF-NOTA-octreotide) PET/CT at multiple sites. The patient chose to receive 1 cycle of Lu-177-DOTATATE peptide receptor radionuclide therapy and experienced radiographic tumor remission and improvement of clinical symptoms after just one cycle of treatment.
CLINICAL NUCLEAR MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Nicolo Formaggio, Mark A. Rubin, Jean-Philippe Theurillat
Summary: Targeting the androgen receptor signaling axis has long been the main strategy for prostate cancer therapy, but stronger inhibition has led to a subset of cancers becoming AR-negative, with a poorer prognosis.
Article
Nutrition & Dietetics
Masayuki Shimizu, Shin Takayama, Akiko Kikuchi, Ryutaro Arita, Rie Ono, Kota Ishizawa, Tadashi Ishii
Summary: The study found that traditional Chinese medicine may be beneficial for patients with advanced pancreatic cancer, prolonging survival and playing a role in disease control and supportive care.
FRONTIERS IN NUTRITION
(2021)
Article
Urology & Nephrology
Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Ian D. Davis, Johann S. de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Rob E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan P. Sade, Oliver Sartor, Howard Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Aurelius Omlin
Summary: The voting results from the 2021 Advanced Prostate Cancer Consensus Conference provide guidance for clinicians and patients in the management of advanced prostate cancer where evidence is scarce. However, treatment decisions should be individualized based on patient characteristics and current clinical evidence.
Review
Medicine, General & Internal
Friedemann Zengerling, Joachim J. Jakob, Stefanie Schmidt, Joerg J. Meerpohl, Anette Blumle, Christine Schmucker, Benjamin Mayer, Frank Kunath
Summary: Degarelix has similar effects to standard androgen suppression therapy in terms of overall survival and quality of life, but may lead to an increase in injection site pain. The effects on cardiovascular events remain uncertain due to limited and high-risk population studies, indicating a need for better-designed long-term studies.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Oncology
Neil E. Fleshner, Shabbir M. H. Alibhai, Kim A. Connelly, Ilidio Martins, Bernhard J. Eigl, Himu Lukka, Armen Aprikian
Summary: Orally administrated agents play a key role in prostate cancer management, but adherence issues can compromise treatment outcomes. This scoping review summarizes data on adherence to oral hormonal therapy in advanced prostate cancer and discusses associated factors and strategies for improving adherence. The findings highlight the need for further research to comprehensively assess adherence due to the low quality and inconsistent reporting of available data.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Oncology
Milap H. Desai, Meghana Parsi, Rashmika R. Potdar
Summary: Prostate cancer is estimated to be the second most common malignancy in men in the USA in 2020, with advanced cases developing resistance to androgen deprivation therapy. Research on newer androgen inhibition therapies and the potential of triple-arm anti-androgen blockade in advanced prostate cancer is ongoing.
Article
Oncology
A. M. Hirst, M. S. Simms, V. M. Mann, N. J. Maitland, D. O'Connell, F. M. Frame
BRITISH JOURNAL OF CANCER
(2015)
Article
Oncology
E. Zoni, G. van der Horst, A. F. van de Merbel, L. Chen, J. K. Rane, R. C. M. Pelger, A. T. Collins, T. Visakorpi, B. E. Snaar-Jagalska, N. J. Maitland, G. van der Pluijm
Article
Cell Biology
Tim M. Wanger, Sharon Dewitt, Anne Collins, Norman J. Maitland, Zaruhi Poghosyan, Vera Knaeuper
CELLULAR SIGNALLING
(2015)
Article
Urology & Nephrology
Jayant K. Rane, Mauro Scaravilli, Antti Ylipaeae, Davide Pellacani, Vincent M. Mann, Matthew S. Simms, Matti Nykter, Anne T. Collins, Tapio Visakorpi, Norman J. Maitland
Editorial Material
Oncology
Norman J. Maitland
Article
Oncology
Frederic R. Santer, Holger H. H. Erb, Su Jung Oh, Florian Handle, Gertrud E. Feiersinger, Birgit Luef, Huajie Bu, Georg Schaefer, Christian Ploner, Martina Egger, Jayant K. Rane, Norman J. Maitland, Helmut Klocker, Iris E. Eder, Zoran Culig
Review
Biochemistry & Molecular Biology
John R. Packer, Norman J. Maitland
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2016)
Editorial Material
Urology & Nephrology
Jayant K. Rane, Alastair P. Droop, Norman J. Maitland
Review
Biochemistry & Molecular Biology
Leanne K. Archer, Fiona M. Frame, Norman J. Maitland
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2017)
Article
Oncology
J. Schmitt, A. Noble, M. Otsuka, P. Berry, N. J. Maitland, M. G. Rumsby
BRITISH JOURNAL OF CANCER
(2014)
Article
Biochemistry & Molecular Biology
D. Pellacani, D. Kestoras, A. P. Droop, F. M. Frame, P. A. Berry, M. G. Lawrence, M. J. Stower, M. S. Simms, V. M. Mann, A. T. Collins, G. P. Risbridger, N. J. Maitland
CELL DEATH AND DIFFERENTIATION
(2014)
Letter
Urology & Nephrology
Jayant K. Rane, Matthew S. Simms, Norman J. Maitland
Review
Biotechnology & Applied Microbiology
Adam M. Hirst, Fiona M. Frame, Norman J. Maitland, Deborah O'Connell
BIOMED RESEARCH INTERNATIONAL
(2014)
Article
Cell & Tissue Engineering
Jayant K. Rane, Alastair P. Droop, Davide Pellacani, Euan S. Polson, Matthew S. Simms, Anne T. Collins, Leo S. D. Caves, Norman J. Maitland
Article
Biotechnology & Applied Microbiology
Ellen Schenk, Magnus Essand, Robert Kraaij, Rachel Adamson, Norman J. Maitland, Chris H. Bangma
HUMAN GENE THERAPY CLINICAL DEVELOPMENT
(2014)